CY1112797T1 - Συμπλοκο σκληροστινης και νογκινης ή χορδινης, και παραγοντες που ρυθμιζουν το σχηματισμο του εν λογω συμπλοκου - Google Patents

Συμπλοκο σκληροστινης και νογκινης ή χορδινης, και παραγοντες που ρυθμιζουν το σχηματισμο του εν λογω συμπλοκου

Info

Publication number
CY1112797T1
CY1112797T1 CY20121100348T CY121100348T CY1112797T1 CY 1112797 T1 CY1112797 T1 CY 1112797T1 CY 20121100348 T CY20121100348 T CY 20121100348T CY 121100348 T CY121100348 T CY 121100348T CY 1112797 T1 CY1112797 T1 CY 1112797T1
Authority
CY
Cyprus
Prior art keywords
chordin
scarstein
nogin
complicated
formation
Prior art date
Application number
CY20121100348T
Other languages
English (en)
Inventor
David G Winkler
John Latham
John Skonier
Diana Shpektor
Trenton Hayes
James Geoghegan
Original Assignee
Ucb Manufacturing, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Manufacturing, Inc. filed Critical Ucb Manufacturing, Inc.
Publication of CY1112797T1 publication Critical patent/CY1112797T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Παρέχονται συνθέσεις και μέθοδοι που σχετίζονται με την απροσδόκητη ειδική σχέση (i) της πρωτεΐνης σύνδεσης ΤGF-βήτα σκληροστίνης με την πρωτεΐνη ανταγωνιστή ΒMΡ χορδίνη για τον σχηματισμό ενός συμπλόκου, και (ii) της πρωτεΐνης σύνδεσης ΤGF-βήτα σκληροστίνης με την πρωτεΐνη ανταγωνιστή ΒΜΡ νογκίνη για τον σχηματισμό ενός συμπλόκου, καθένα από τα οποία σύμπλοκα είναι ανίκανο σύνδεσης σε κάποιο μέλος της υπεροικογένειας ΤGF-βήτα όπως μια ΒΜΡ. Η εφεύρεση παρέχει απομονωμένα σύμπλοκα για χρήση σε δοκιμασίες προκαταρκτικής αξιολόγησης για την πιστοποίηση παραγόντων που ρυθμίζουν την οστική ορυκτοποίηση, και προσφέρει άλλα σχετικά πλεονεκτήματα.
CY20121100348T 2003-03-14 2012-04-09 Συμπλοκο σκληροστινης και νογκινης ή χορδινης, και παραγοντες που ρυθμιζουν το σχηματισμο του εν λογω συμπλοκου CY1112797T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45525303P 2003-03-14 2003-03-14
EP04720380A EP1608399B1 (en) 2003-03-14 2004-03-12 Complex of sclerostin and noggin or chordin, and agents that modulate the formation of said complex

Publications (1)

Publication Number Publication Date
CY1112797T1 true CY1112797T1 (el) 2016-02-10

Family

ID=33029975

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100348T CY1112797T1 (el) 2003-03-14 2012-04-09 Συμπλοκο σκληροστινης και νογκινης ή χορδινης, και παραγοντες που ρυθμιζουν το σχηματισμο του εν λογω συμπλοκου

Country Status (15)

Country Link
US (1) US7226902B2 (el)
EP (1) EP1608399B1 (el)
JP (1) JP4660471B2 (el)
AT (1) ATE540977T1 (el)
AU (1) AU2004222317B2 (el)
CA (1) CA2519131C (el)
CY (1) CY1112797T1 (el)
DK (1) DK1608399T3 (el)
ES (1) ES2379689T3 (el)
MX (1) MXPA05009805A (el)
NZ (1) NZ542587A (el)
PL (2) PL1608399T3 (el)
PT (1) PT1608399E (el)
SI (1) SI1608399T1 (el)
WO (1) WO2004082608A2 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI9915679B8 (pt) 1998-11-27 2021-05-25 Darwin Discovery Ltd composições e métodos para aumentar a mineralização óssea
RS20050934A (en) * 2003-06-16 2008-04-04 Celltech R. & D. Inc., Antibodies specific for sclerostin and methods fo r increasing bone mineralization
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
AU2006289667A1 (en) * 2005-09-08 2007-03-15 Apollo Life Sciences Limited Noggin and chimeric molecules thereof
EP2069558B1 (en) * 2006-10-02 2013-05-01 Sea Lane Biotechnologies,llc. Design and construction of diverse synthetic peptide and polypeptide libraries
EP2460828A3 (en) * 2006-11-10 2012-08-08 UCB Pharma, S.A. Antibodies and diagnostics
US20100036091A1 (en) * 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
WO2008092894A1 (en) * 2007-02-02 2008-08-07 Novartis Ag Modulators of sclerostin binding partners for treating bone-related disorders
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
US20110044978A1 (en) * 2007-12-14 2011-02-24 Amgen Inc. Method for treating bone fracture
EP2349332B1 (en) * 2008-11-13 2019-10-23 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation bmp-6
KR101163171B1 (ko) * 2009-01-20 2012-07-19 (주)케어젠 노긴?유래 펩타이드 및 그의 용도
DK3195880T3 (da) 2010-05-14 2020-03-02 Amgen Inc Højkoncentrerede anti-sclerostin-antistofformuleringer
MX2013010011A (es) 2011-03-01 2014-10-24 Amgen Inc Agentes de unión biespecífica.
MA35009B1 (fr) 2011-03-25 2014-04-03 Amgen Inc Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
SI2739311T1 (en) 2011-08-04 2018-07-31 Amgen Inc. Method for the treatment of bone defect defects
JP6363954B2 (ja) 2011-12-28 2018-07-25 アムジエン・インコーポレーテツド 抗スクレロスチン抗体の使用による歯槽骨消失の治療方法
EP3626267A1 (en) 2012-07-05 2020-03-25 UCB Pharma, S.A. Treatment for bone diseases
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
WO2018115879A1 (en) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
SG11202008206TA (en) 2018-03-30 2020-09-29 Amgen Inc C-terminal antibody variants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846770A (en) * 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
WO1996039486A1 (en) * 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Human ccn-like growth factor
US5989909A (en) * 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
CA2323754C (en) 1998-03-30 2012-03-20 Dow Agrosciences Llc Modification of fatty acid composition in plants by expression of an aspergillus nidulans delta-9 coa desaturase
BRPI9915679B8 (pt) * 1998-11-27 2021-05-25 Darwin Discovery Ltd composições e métodos para aumentar a mineralização óssea
CA2401175A1 (en) 2000-03-02 2001-09-07 Amgen, Inc. Chordin-like-2 molecules and uses thereof

Also Published As

Publication number Publication date
ATE540977T1 (de) 2012-01-15
JP2006522103A (ja) 2006-09-28
EP1608399B1 (en) 2012-01-11
JP4660471B2 (ja) 2011-03-30
AU2004222317A1 (en) 2004-09-30
DK1608399T3 (da) 2012-04-02
PT1608399E (pt) 2012-04-13
WO2004082608A2 (en) 2004-09-30
ES2379689T3 (es) 2012-04-30
CA2519131A1 (en) 2004-09-30
WO2004082608A9 (en) 2005-03-17
SI1608399T1 (sl) 2012-05-31
US7226902B2 (en) 2007-06-05
AU2004222317B2 (en) 2010-08-19
US20050085418A1 (en) 2005-04-21
NZ542587A (en) 2008-05-30
EP1608399A2 (en) 2005-12-28
CA2519131C (en) 2014-07-08
PL378566A1 (pl) 2006-05-02
WO2004082608A3 (en) 2005-01-20
PL1608399T3 (pl) 2012-09-28
MXPA05009805A (es) 2006-04-18

Similar Documents

Publication Publication Date Title
CY1112797T1 (el) Συμπλοκο σκληροστινης και νογκινης ή χορδινης, και παραγοντες που ρυθμιζουν το σχηματισμο του εν λογω συμπλοκου
CY1116525T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
RS20050934A (en) Antibodies specific for sclerostin and methods fo r increasing bone mineralization
MEP3108A (xx) Kompozicije i postupci za povećanje mineralizacije kostiju
ES2523837T3 (es) Agentes de unión específica al factor de crecimiento de hepatocitos
NO20063569L (no) M-CSF-spesifikt monoklonalt antistoff og anvendelse derav
CY1116377T1 (el) Αναστολεις της ανθρωπινης πρωτεϊνικης φωσφατασης της τυροσινης και μεθοδοι χρησης
CR20120587A (es) Moléculas de unión al antígeno que fijan egfr, vectores que las codifican y uso de las mismas
MY174493A (en) Binding agents
AR060017A1 (es) Composiciones y metodos de uso para anticuerpos de dickkopf -1
DK2135881T3 (da) Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
AR055152A1 (es) Anticuerpos monoclonales humanos para la quinasa -1 tipo receptor de activina
CY1110689T1 (el) Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
DE60334645D1 (de) Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
PE20081392A1 (es) Moleculas de enlace de lingo
AR038563A1 (es) Composicion de ziprasidona y controles sinteticos
BRPI0507019A (pt) composição, uso de anticorpo, anticorpo, uso de msrv/herv-w env-su
CR10069A (es) Anticuerpos anti-ox40l y métodos que los utilizan referencia cruzada con solicitudes relacionadas
EA200870208A1 (ru) Конструкт однодоменного антитела
BRPI0519429A2 (pt) composiÇço adequada para melhorar funÇço renal em um animal, mÉtodo para melhorar a funÇço renal em um animal, kit adequado para administrar composiÇÕes para melhorar a funÇço renal a um animal, meio para comunicar informaÇço, e, uso de uma composiÇço
BRPI0607323B8 (pt) composições, usos de polipeptídeos e de anticorpos, bem como kits para a detecção de anticorpo que se liga especificamente a um polipeptídeo
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.